Pathogenesis and Bisphosphonate Treatment of Skeletal Events and Bone Pain in Metastatic Cancer: Focus on Ibandronate

Publisher： Karger

E-ISSN： 2296-5262|35|6|380-387

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.35, Iss.6, 2012-05, pp. : 380-387

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg

By Epstein S.   Jeglitsch M.   McCloskey E.  

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 2951-2960

Informa Healthcare

Access to resources Recommend Favorite

Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain

By  

Oncology Research and Treatment, Vol. 35, Iss. 5, 2012-04 ,pp. : 254-258

Karger

Access to resources Recommend Favorite

The Cost of Treatment of Skeletal-Related Events in Patients with Bone Metastases from Lung Cancer

By  

Oncology, Vol. 67, Iss. 5-6, 2005-02 ,pp. : 390-396

Karger

Access to resources Recommend Favorite

An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting

By Barrett-Lee Peter   Bloomfield Danny   Dougherty Lisa   Harries Martyn   Laing Robert   Patel Hetal   Walker Mel  

Current Medical Research and Opinion, Vol. 23, Iss. 7, 2007-07 ,pp. : 1575-1582

Informa Healthcare

Access to resources Recommend Favorite

Opioids for Metastatic Bone Pain

By  

Oncology, Vol. 74, Iss. 1, 2008-08 ,pp. : 52-54

Karger

Access to resources Recommend Favorite